Search Within

Genitourinary Oncology Service

  1. "Min Yuen Teo"
Formats
  1. Meeting Abstract (57)
  2. Journal Article (43)
  3. Review (4)
  4. Editorial (2)
  5. Book Section (1)
Groups
  1. Department of Medicine (107)
  2. Solid Tumor Oncology Division (107)
  3. Department of Pathology and Laboratory Medicine (58)
  4. Hematology-Oncology Fellows (51)
  5. Surgery (51)
  6. Weinberg Fellows (51)

More Groups

People
  1. Min Yuen Teo (107)
  2. Jonathan Rosenberg (77)
  3. Gopakumar Iyer (70)
  4. Dean Bajorin (60)
  5. Hikmat Al-Ahmadie (52)
  6. Samuel Funt (47)

More People

Years
  1. 2025 (6)
  2. 2024 (13)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (12)
  6. 2020 (11)

More Years

Publications
  1. Journal of Clinical Oncology (45)
  2. Annals of Oncology (5)
  3. Cancer Research (5)
  4. Clinical Cancer Research (4)
  5. Modern Pathology (4)
  6. European Urology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (47)
  2. Nature Publishing Group (12)
  3. American Association for Cancer Research (9)
  4. Oxford University Press (5)
  5. Elsevier Science, Inc. (4)
  6. Lippincott Williams & Wilkins (4)

More Publishers

Results (107)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Modulating the PPARĪ³ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
    Journal Article

    Chang, K.; Delavan, H. M.; Yip, E.; Kasap, C.; Zhu, J.; Lodha, R.; Liao, S. Y.; Berman, S. C.; Carretero-Gonzalez, A.; Basar, M.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma
    Journal Article

    Chu, C. E.; Chen, Z.; Whiting, K.; Ostrovnaya, I.; Lenis, A. T.; Clinton, T. N.; Rammal, R.; Ozcan, G. G.; Akbulut, D.; Basar, M.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma
    Journal Article

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G.; Berg, S.; Kim, W. Y.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save